<DOC>
	<DOC>NCT00127595</DOC>
	<brief_summary>This is a phase II monocentric study of oxaliplatin (Ox) in combination with gemcitabine (Gem; GEMOX) in patients (pts) with advanced/metastatic transitional cell carcinoma (TCC) of the urothelial tract.</brief_summary>
	<brief_title>Oxaliplatin With Gemcitabine in Patients With Carcinoma of the Urothelial Tract</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Transitional Cell</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>Transitional cell carcinoma Histologicallyproven Locally advanced unresectable or metastatic With at least one measurable target Informed consent signed Previous chemotherapy Previous radiotherapy Performance status &gt;=2 Peripheral neuropathy &gt;=1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2005</verification_date>
	<keyword>carcinoma of the urothelial tract</keyword>
</DOC>